{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:10:20Z","timestamp":1750828220329},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,21]]},"DOI":"10.7759\/cureus.60773","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:02:15Z","timestamp":1716303735000},"source":"Crossref","is-referenced-by-count":1,"title":["A Unique Case of Non-paraneoplastic Lambert-Eaton Myasthenic Syndrome Treated With Subcutaneous Immunoglobulin: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Sojung K","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie G","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer MJ","year":"2011","unstructured":"Titulaer MJ, Maddison P, Sont JK, et al.. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011, 29:902-8. 10.1200\/JCO.2010.32.0440","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga AR","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022, 21:176-88. 10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.008","article-title":"Lambert-Eaton myasthenic syndrome","volume":"36","author":"Kesner VG","year":"2018","unstructured":"Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018, 36:379-94. 10.1016\/j.ncl.2018.01.008","journal-title":"Neurol Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S192588","article-title":"Lambert-Eaton myasthenic syndrome: early diagnosis is key","volume":"9","author":"Ivanovski T","year":"2019","unstructured":"Ivanovski T, Miralles F. Lambert-Eaton myasthenic syndrome: early diagnosis is key. Degener Neurol Neuromuscul Dis. 2019, 9:27-37. 10.2147\/DNND.S192588","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-009-0010-z","article-title":"Lambert-Eaton myasthenic syndrome","volume":"11","author":"Weimer MB","year":"2009","unstructured":"Weimer MB, Wong J. Lambert-Eaton myasthenic syndrome. Curr Treat Options Neurol. 2009, 11:77-84. 10.1007\/s11940-009-0010-z","journal-title":"Curr Treat Options Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i3.293","article-title":"Voltage gated calcium channel antibody-related neurological diseases","volume":"3","author":"Bekircan-Kurt CE","year":"2015","unstructured":"Bekircan-Kurt CE, Derle \u00c7ift\u00e7i E, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases. 2015, 3:293-300. 10.12998\/wjcc.v3.i3.293","journal-title":"World J Clin Cases"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008747","article-title":"Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome","volume":"94","author":"Lipka AF","year":"2020","unstructured":"Lipka AF, Boldingh MI, van Zwet EW, et al.. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020, 94:e511-20. 10.1212\/WNL.0000000000008747","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/973808","article-title":"Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy","volume":"2011","author":"Gilhus NE","year":"2011","unstructured":"Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011, 2011:973808. 10.4061\/2011\/973808","journal-title":"Autoimmune Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420204","article-title":"Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse","volume":"42","author":"Waterman SA","year":"1997","unstructured":"Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol. 1997, 42:147-56. 10.1002\/ana.410420204","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000130254.27019.14","article-title":"The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands","volume":"63","author":"Wirtz PW","year":"2004","unstructured":"Wirtz PW, van Dijk JG, van Doorn PA, et al.. The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology. 2004, 63:397-8. 10.1212\/01.wnl.0000130254.27019.14","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019864574","article-title":"Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug","volume":"54","author":"Yoon CH","year":"2020","unstructured":"Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020, 54:56-63. 10.1177\/1060028019864574","journal-title":"Ann Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63432-0.00024-4","article-title":"Neuromuscular junction disorders","volume":"133","author":"Verschuuren J","year":"2016","unstructured":"Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handb Clin Neurol. 2016, 133:447-66. 10.1016\/B978-0-444-63432-0.00024-4","journal-title":"Handb Clin Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.065","article-title":"Lambert-Eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders DB","year":"2003","unstructured":"Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003, 998:500-8. 10.1196\/annals.1254.065","journal-title":"Ann N Y Acad Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-1104-5","article-title":"IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status","volume":"252","author":"Illa I","year":"2005","unstructured":"Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol. 2005, 252:I14-8. 10.1007\/s00415-005-1104-5","journal-title":"J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116497","article-title":"Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?","volume":"408","author":"Allen JA","year":"2020","unstructured":"Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?. J Neurol Sci. 2020, 408:116497. 10.1016\/j.jns.2019.116497","journal-title":"J Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-41135","article-title":"Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"23","author":"Newsom-Davis J","year":"2003","unstructured":"Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol. 2003, 23:191-8. 10.1055\/s-2003-41135","journal-title":"Semin Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie GO","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, et al.. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010, 17:893-902. 10.1111\/j.1468-1331.2010.03019.x","journal-title":"Eur J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison P","year":"2011","unstructured":"Maddison P, McConville J, Farrugia ME, et al.. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011, 82:671-3. 10.1136\/jnnp.2009.197632","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/201844-a-unique-case-of-non-paraneoplastic-lambert-eaton-myasthenic-syndrome-treated-with-subcutaneous-immunoglobulin-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:02:57Z","timestamp":1716303777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/201844-a-unique-case-of-non-paraneoplastic-lambert-eaton-myasthenic-syndrome-treated-with-subcutaneous-immunoglobulin-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.60773","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}